FDA warns iVisitDoc over website claims that compounded semaglutide is equivalent to Wegovy and Ozempic, calling the drugs misbranded.
What happened
In August 2025, FDA reviewed the website https://ivisitdoc.com and observed that it offers various compounded semaglutide drug products. FDA said website claims, including that the products have the same active ingredients as Wegovy and Ozempic and that they have “Clinically Validated Ingredients,” are false or misleading because compounded drugs are not FDA-approved. FDA cited these as misbranding violations.
What FDA found
The website said compounded semaglutide has the same active ingredients as Wegovy and Ozempic, which FDA says misleadingly implies it is the same as FDA-approved products.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]The website claimed “Clinically Validated Ingredients,” which FDA says is false or misleading for compounded semaglutide products that are not FDA-approved.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]FDA says the compounded semaglutide products are misbranded because their labeling and advertising are false or misleading.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]The misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce and delivering or offering to deliver them is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells iVisitDoc to take immediate action, including ceasing and desisting from the misleading language, and to send a written response within 15 working days of receipt. The response must describe specific steps taken, explain how recurrence will be prevented, and include related documentation.
Who should pay attention
- telehealth companies selling compounded semaglutide
- marketing teams for compounded drug websites
- compounding pharmacies and their marketing partners
This is a summary. Read the original letter on fda.gov.